In a bid to revolutionize digital-implant workflow in dental care,DENTSPLY SIRONA Inc. (XRAY - Free Report) recently launched a single tooth replacement solution — Azento — in the United States.
It will be available in Canada and Europe by 2019.
What is Azento?
Azento reduces the risk of complications in single-tooth replacement procedures.
It is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment. It revolutionizes the digital implant workflow by restructuring implant-planning service, purchase and delivery.
Courtesy of the platform, patients will benefit from the reduced number of visits and chair time.
Azento leverages on DENTSPLY’s flagship Astra Tech Implant System and Xive units. It is also based on Atlantis custom healing abutment and optional temporary restoration.
Tooth Replacement Market Forecast
A report by the Meticulous Research states that the global tooth replacement market is expected to reach $13,035.2 million by 2022, at a CAGR of 6.9%.
R&D Boosts Product Innovation
DENTSPLY’s overall growth strategy rests on product innovation. The company pursues several research and development (R&D) initiatives to support technological development.
The Azento launch is also a perfect example of the company’s strong R&D focus as it is made for patients and dental professionals. It has a prosthetically driven treatment plan depending upon each patient's digital scans.
Management is targeting an investment of more than $160 million in innovation. The company expects to launch more than 30 major products by the end of 2018.
Other products like WaveOne GOLD, X-Smart iQ, VDW and CONNECT Drive are expected to boost penetration in Europe. Growing preventive and restorative product portfolio is expected to drive market expansion in the continent. The company’s diverse product portfolio and recurring revenue base are key growth catalysts in the long run.
Zacks Rank & Price Performance
DENTSPLY’s price movement has been unfavorable in the past year. The company’s shares have lost 34.7%, against the industry’s rise of 14.6%. The current level is also lower than S&P 500's return of 16.1%.
The stock has a Zacks Rank #4 (Sell).
Want More from the MedTech Space?
A few better-ranked stocks in the MedTech space are Penumbra, Inc (PEN - Free Report) , Masimo Corporation (MASI - Free Report) and Illumina, Inc (ILMN - Free Report) . Penumbra and Illumina sport a Zacks Rank #1 (Strong Buy). Masimo currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra has a long-term expected earnings growth rate of 20%, while the same for Masimo and Illumina is pegged at 14.8% and 22.1%, respectively.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>